Flibanserin, which aims to restore lost libido in women, has been twice rejected by the F.D.A., which cited limited effectiveness as well as side effects. The drug will go before agency advisers again on Thursday.
ANDREW POLLACK, New York Times
Sun, 05/31/2015 - 6:23pm
Flibanserin, which aims to restore lost libido in women, has been twice rejected by the F.D.A., which cited limited effectiveness as well as side effects. The drug will go before agency advisers again on Thursday.